Weaver Capital Management LLC Has $1.76 Million Position in Johnson & Johnson $JNJ

Weaver Capital Management LLC reduced its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,549 shares of the company’s stock after selling 712 shares during the quarter. Weaver Capital Management LLC’s holdings in Johnson & Johnson were worth $1,764,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock worth $42,000 after purchasing an additional 86 shares during the last quarter. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $47,000. 1248 Management LLC bought a new stake in shares of Johnson & Johnson during the first quarter worth $48,000. von Borstel & Associates Inc. bought a new stake in shares of Johnson & Johnson during the first quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the first quarter worth $52,000. Institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on JNJ shares. Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Sanford C. Bernstein upped their target price on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Finally, The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $192.94.

Johnson & Johnson Price Performance

Shares of JNJ opened at $190.66 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $192.10. The stock has a market cap of $459.16 billion, a P/E ratio of 20.39, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The stock’s 50-day moving average price is $178.48 and its two-hundred day moving average price is $163.76.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $24.02 billion for the quarter. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.